Mesoporous Silica Nanoparticle-Based Combination of Niclosamide and Doxorubicin: Effect of Treatment Regimens on Breast Cancer Subtypes

2021 ◽  
Author(s):  
Garima Lohiya ◽  
Dhirendra S. Katti
Keyword(s):  
Breast Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticle ◽  
Breast Cancer Subtypes ◽  
Mesoporous Silica Nanoparticle ◽  
Cancer Subtypes ◽  
Treatment Regimens ◽  
Effect Of Treatment

scholarly journals An ingenious non-spherical mesoporous silica nanoparticle cargo with curcumin induces mitochondria-mediated apoptosis in breast cancer (MCF-7) cells

Oncotarget ◽  
2019 ◽  
Vol 10 (11) ◽  
pp. 1193-1208 ◽  
Author(s):  
Lakshminarasimhan Harini ◽  
Sweta Srivastava ◽  
George Peter Gnanakumar ◽  
Bose Karthikeyan ◽  
Cecil Ross ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticle ◽  
Mesoporous Silica Nanoparticle ◽  
Mcf 7

Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy

2020 ◽  
Vol 8 (10) ◽  
pp. 2939-2954 ◽  
Author(s):  
Manisha Ahir ◽  
Priyanka Upadhyay ◽  
Avijit Ghosh ◽  
Sushmita Sarker ◽  
Saurav Bhattacharya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mesoporous Silica ◽  
Triple Negative Breast Cancer ◽  
Conjugated Polymer ◽  
Triple Negative ◽  
Mesoporous Silica Nanoparticles ◽  
Silica Nanoparticle ◽  
Breast Cancer Therapy ◽  
Mesoporous Silica Nanoparticle ◽  
Efficient Delivery

Cationic Mesoporous silica Nanoparticle coated with hyaluronic acid conjugated polymer (HA-Dual miRNA Np) facilitated enhanced dual miRNA loading, efficient delivery and significantly inhibited tumor growth as well as retarded metastasis in triple-negative breast cancer.

scholarly journals Mesoporous silica nanoparticle-based intelligent drug delivery system for bienzyme-responsive tumour targeting and controlled release

2018 ◽  
Vol 5 (1) ◽  
pp. 170986 ◽  
Author(s):  
Yang Zhang ◽  
Juan Xu
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Controlled Release ◽  
Drug Release ◽  
Mesoporous Silica ◽  
Cancer Cell ◽  
Silica Nanoparticle ◽  
Cell Targeting ◽  
Mesoporous Silica Nanoparticle ◽  
Cancer Cell Targeting

This paper proposes a novel type of multifunctional envelope-type mesoporous silica nanoparticle (MSN) to achieve cancer cell targeting and drug-controlled release. In this system, MSNs were first modified by active targeting moiety hyaluronic acid (HA) for breast cancer cell targeting and hyaluronidases (Hyal)-induced intracellular drug release. Then gelatin, a proteinaceous biopolymer, was grafted onto the MSNs to form a capping layer via glutaraldehyde-mediated cross-linking. To shield against unspecific uptake of cells and prolong circulation time, the nanoparticles were further decorated with poly(ethylene glycol) polymers (PEG) to obtain MSN@HA-gelatin-PEG (MHGP). Doxorubicin (DOX), as a model drug, was loaded into PEMSN to assess the breast cancer cell targeting and drug release behaviours. In vitro study revealed that PEG chains protect the targeting ligand and shield against normal cells. After reaching the breast cancer cells, MMP-2 overpressed by cells hydrolyses gelatin layer to deshield PEG and switch on the function of HA. As a result, DOX-loaded MHGP was selectively trapped by cancer cells through HA receptor-mediated endocytosis and subsequently release DOX due to Hyal-catalysed degradation of HA. This system presents successful bienzyme-responsive targeting drug delivery in an optimal fashion and provides potential applications for targeted cancer therapy.

scholarly journals Differential expression of the BCAT isoforms between breast cancer subtypes

Breast Cancer ◽  
2020 ◽  
Author(s):  
Mai Ahmed Shafei ◽  
Arwa Flemban ◽  
Carl Daly ◽  
Paul Kendrick ◽  
Paul White ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Metabolism ◽  
Breast Cancer Subtypes ◽  
Metabolic Phenotype ◽  
Luminal A ◽  
Cancer Subtypes ◽  
Luminal B ◽  
Treatment Regimens ◽  
Enhanced Expression ◽  
Branched Chain

Abstract Background Biological characterisation of breast cancer subtypes is essential as it informs treatment regimens especially as different subtypes have distinct locoregional patterns. This is related to metabolic phenotype, where altered cellular metabolism is a fundamental adaptation of cancer cells during rapid proliferation. In this context, the metabolism of the essential branched-chain amino acids (BCAAs), catalysed by the human branched-chain aminotransferase proteins (hBCAT), offers multiple benefits for tumour growth. Upregulation of the cytosolic isoform of hBCAT (hBCATc), regulated by c-Myc, has been demonstrated to increase cell migration, tumour aggressiveness and proliferation in gliomas, ovarian and colorectal cancer but the importance of the mitochondrial isoform, hBCATm has not been fully investigated. Methods Using immunohistochemistry, the expression profile of metabolic proteins (hBCAT, IDH) was assessed between breast cancer subtypes, HER2 + , luminal A, luminal B and TNBC. Correlations between the percentage and the intensity of protein expression/co-expression with clinical parameters, such as hormone receptor status, tumour stage, lymph-node metastasis and survival, were determined. Results We show that hBCATc expression was found to be significantly associated with the more aggressive HER2 + and luminal B subtypes, whilst hBCATm and IDH1 associated with luminal A subtype. This was concomitant with better prognosis indicating a differential metabolic reliance between these two subtypes, in which enhanced expression of IDH1 may replenish the α-ketoglutarate pool in cells with increased hBCATm expression. Conclusion The cytosolic isoform of BCAT is associated with tumours that express HER2 receptors, whereas the mitochondrial isoform is highly expressed in tumours that are ER + , indicating that the BCAT proteins are regulated through different signalling pathways, which may lead to the identification of novel targets for therapeutic applications targeting dysregulated cancer metabolism.

Identification of new therapeutic leads for triple negative breast cancer subtypes

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Therapeutic Leads
Sign in / Sign up

Export Citation Format

Share Document